Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;129(5-6):755-771.
doi: 10.1007/s00702-022-02480-x. Epub 2022 Mar 16.

Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease

Affiliations
Review

Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer's disease

Xian Zhou et al. J Neural Transm (Vienna). 2022 Jun.

Abstract

Prof. Dr. Peter Riederer, the former Head of the Neurochemistry Department of the Psychiatry and Psychotherapy Clinic at the University of Würzburg (Germany), has been one of the pioneers of research into oxidative stress in Parkinson's and Alzheimer's disease (AD). This review will outline how his scientific contribution to the field has opened a new direction for AD treatment beyond "plaques and tangles". In the 1990s, Prof. Riederer was one of the first scientists who proposed oxidative stress and neuroinflammation as one of the major contributors to Alzheimer's disease, despite the overwhelming support for the "amyloid-only" hypothesis at the time, which postulated that the sole and only cause of AD is β-amyloid. His group also highlighted the role of advanced glycation end products, sugar and dicarbonyl-derived protein modifications, which crosslink proteins into insoluble aggregates and potent pro-inflammatory activators of microglia. For the treatment of chronic neuroinflammation, he and his group suggested that the most appropriate drug class would be cytokine-suppressive anti-inflammatory drugs (CSAIDs) which have a broader anti-inflammatory action range than conventional non-steroidal anti-inflammatory drugs. One of the most potent CSAIDs is curcumin, but it suffers from a variety of pharmacokinetic disadvantages including low bioavailability, which might have tainted many human clinical trials. Although a variety of oral formulations with increased bioavailability have been developed, curcumin's absorption after oral delivery is too low to reach therapeutic concentrations in the micromolar range in the systemic circulation and the brain. This review will conclude with evidence that rectally applied suppositories might be the best alternatives to oral medications, as this route will be able to evade first-pass metabolism in the liver and achieve high concentrations of curcumin in plasma and tissues, including the brain.

Keywords: Brain; Curcumin; Dementia; Glycation; Inflammation; Suppositories.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Alsema AM, Jiang Q, Kracht L, Gerrits E, Dubbelaar ML, Miedema A, Brouwer N, Hol EM, Middeldorp J, van Dijk R, Woodbury M, Wachter A, Xi S, Moller T, Biber KP, Kooistra SM, Boddeke E, Eggen BJL (2020) Profiling Microglia From Alzheimer’s disease donors and non-demented elderly in acute human postmortem cortical tissue. Front Mol Neurosci 13:134. https://doi.org/10.3389/fnmol.2020.00134 - DOI - PubMed - PMC
    1. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ (2000) Microglia, amyloid and dementia in Alzheimer disease. A correlative study. Neurobiol Aging 21(1):39–47. https://doi.org/10.1016/s0197-4580(00)00094-4 - DOI - PubMed
    1. Bales KR, Du Y, Holtzman D, Cordell B, Paul SM (2000) Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging 21(3):427–432. https://doi.org/10.1016/s0197-4580(00)00143-3 (discussion 451–423) - DOI - PubMed
    1. Bauer J, Strauss S, Volk B, Berger M (1991) IL-6-mediated events in Alzheimer’s disease pathology. Immunol Today 12(11):422 - DOI
    1. Baum W, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28(1):110–113. https://doi.org/10.1097/jcp.0b013e318160862c - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources